Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Paolo Antonio Ascierto,Ester Simeone,Vanna Chiarion Sileni,Jacopo Pigozzo,Michele Maio,Maresa Altomonte,Michele Del Vecchio,Lorenza Di Guardo,Paolo Marchetti,Ruggero Ridolfi,Francesco Cognetti,Alessandro Testori,Maria Grazia Bernengo,Michele Guida,Riccardo Marconcini,Mario Mandalà,Carolina Cimminiello,Gaetana Rinaldi,Massimo Aglietta,Paola Queirolo

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

2014

Background Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP).

Keywords:

Clinical trial
Ipilimumab
Cohort
Melanoma
Immunology
Cohort study
Expanded access
Medicine
advanced melanoma
treatment outcome
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

132

Citations